WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407228
Description: BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation. NVP-BAW2881 inhibited proliferation, migration, and tube formation by human umbilical vein endothelial cells and lymphatic endothelial cells in vitro. NVP-BAW2881 reduced the number of blood and lymphatic vessels and infiltrating leukocytes in the skin, and normalized the epidermal architecture. NVP-BAW2881 also displayed strong anti-inflammatory effects in models of acute inflammation; pretreatment with topical NVP-BAW2881 significantly inhibited VEGF-A-induced vascular permeability in the skin of pigs and mice.
MedKoo Cat#: 407228
Chemical Formula: C22H15F3N4O2
Exact Mass: 424.1147
Molecular Weight: 424.3832
Elemental Analysis: C, 62.26; H, 3.56; F, 13.43; N, 13.20; O, 7.54
BAW2881 purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: BAW2881; BAW-2881; BAW 2881; NVP-BAW2881; NVP-BAW-2881; NVP-BAW 2881.
IUPAC/Chemical Name: 6-((2-aminopyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide
InChi Key: MLLQJNIKDWEEFT-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H15F3N4O2/c23-22(24,25)14-4-2-5-15(12-14)28-20(30)18-6-1-3-13-11-16(7-8-17(13)18)31-19-9-10-27-21(26)29-19/h1-12H,(H,28,30)(H2,26,27,29)
SMILES Code: O=C(C1=C2C=CC(OC3=NC(N)=NC=C3)=CC2=CC=C1)NC4=CC=CC(C(F)(F)F)=C4
The following data is based on the product molecular weight 424.3832 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Halin C, Fahrngruber H, Meingassner JG, Bold G, Littlewood-Evans A, Stuetz A,
Detmar M. Inhibition of chronic and acute skin inflammation by treatment with a
vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J
Pathol. 2008 Jul;173(1):265-77. doi: 10.2353/ajpath.2008.071074. Epub 2008 Jun 5.
PubMed PMID: 18535184; PubMed Central PMCID: PMC2438303.